Institution
University of Arkansas for Medical Sciences
Education•Little Rock, Arkansas, United States•
About: University of Arkansas for Medical Sciences is a education organization based out in Little Rock, Arkansas, United States. It is known for research contribution in the topics: Population & Health care. The organization has 14077 authors who have published 26012 publications receiving 973592 citations. The organization is also known as: UAMS.
Topics: Population, Health care, Medicine, Poison control, Multiple myeloma
Papers published on a yearly basis
Papers
More filters
••
Oregon Health & Science University1, University of South Dakota2, Technische Universität München3, Great Ormond Street Hospital4, University College London5, UCL Institute of Neurology6, Necker-Enfants Malades Hospital7, University of Arkansas for Medical Sciences8, McMaster University Medical Centre9, Icahn School of Medicine at Mount Sinai10, Albany Medical College11, Maastricht University Medical Centre12, Guy's and St Thomas' NHS Foundation Trust13, The Queen's Medical Center14, University Hospitals Bristol NHS Foundation Trust15, University Hospitals Birmingham NHS Foundation Trust16
TL;DR: Beta-propeller protein-associated neurodegeneration, the only X-linked disorder of neurodegenersation with brain iron accumulation, is associated with de novo mutations in WDR45 and is recognizable by a unique combination of clinical, natural history and neuroimaging features.
Abstract: Neurodegenerative disorders with high iron in the basal ganglia encompass an expanding collection of single gene disorders collectively known as neurodegeneration with brain iron accumulation. These disorders can largely be distinguished from one another by their associated clinical and neuroimaging features. The aim of this study was to define the phenotype that is associated with mutations in WDR45, a new causative gene for neurodegeneration with brain iron accumulation located on the X chromosome. The study subjects consisted of WDR45 mutation-positive individuals identified after screening a large international cohort of patients with idiopathic neurodegeneration with brain iron accumulation. Their records were reviewed, including longitudinal clinical, laboratory and imaging data. Twenty-three mutation-positive subjects were identified (20 females). The natural history of their disease was remarkably uniform: global developmental delay in childhood and further regression in early adulthood with progressive dystonia, parkinsonism and dementia. Common early comorbidities included seizures, spasticity and disordered sleep. The symptoms of parkinsonism improved with l-DOPA; however, nearly all patients experienced early motor fluctuations that quickly progressed to disabling dyskinesias, warranting discontinuation of l-DOPA. Brain magnetic resonance imaging showed iron in the substantia nigra and globus pallidus, with a ‘halo’ of T1 hyperintense signal in the substantia nigra. All patients harboured de novo mutations in WDR45, encoding a beta-propeller protein postulated to play a role in autophagy. Beta-propeller protein-associated neurodegeneration, the only X-linked disorder of neurodegeneration with brain iron accumulation, is associated with de novo mutations in WDR45 and is recognizable by a unique combination of clinical, natural history and neuroimaging features.
195 citations
••
TL;DR: In this paper, the authors used oligonucleotide microarrays to identify genes with a differential pattern of expression between invasive cervical carcinomas (CVX) and normal cervical keratinocytes (NCK).
195 citations
••
TL;DR: Evidence for the role of apoptotic pathways in ischemic acute renal failure is described, the potential mechanisms that may participate in this model of acute renal tubular injury are considered, and a better understanding of the mechanisms of apoptosis could lead to safer and more specific therapeutic interventions for acute kidney failure.
195 citations
••
TL;DR: Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.
195 citations
••
TL;DR: The data demonstrate that NY-ESO-1 is frequently expressed in MM with CA and is capable of eliciting spontaneous humoral and T-cell immunity, and should be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM.
195 citations
Authors
Showing all 14187 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hagop M. Kantarjian | 204 | 3708 | 210208 |
Yusuke Nakamura | 179 | 2076 | 160313 |
Kenneth C. Anderson | 178 | 1138 | 126072 |
David R. Williams | 178 | 2034 | 138789 |
Yang Yang | 171 | 2644 | 153049 |
John E. Morley | 154 | 1377 | 97021 |
Jeffrey L. Cummings | 148 | 833 | 116067 |
Hugh A. Sampson | 147 | 816 | 76492 |
Michael J. Keating | 140 | 1169 | 76353 |
Kristine Yaffe | 136 | 794 | 72250 |
Nancy J. Cox | 135 | 778 | 109195 |
Stephen W. Scherer | 135 | 685 | 85752 |
Nikhil C. Munshi | 134 | 906 | 67349 |
Siamon Gordon | 131 | 420 | 77948 |
Jian-Guo Bian | 128 | 1219 | 80964 |